|By PR Newswire||
|August 18, 2014 07:20 PM EDT||
FREDERICK, Md., Aug. 18, 2014 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices said that its EVP Dr. Deepak Kotak was interviewed by CEOLIVE.TV as part of its Executive Interview Series.
The entire interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel
In the interview Dr. Kotak explains to investors the unique advantages of BioElectronics patented technology to satisfy the unmet medical needs of millions of consumers. He explains how the Company is positioned to serve new, large medical markets with its drug-free, non-invasive technology.
Before joining BioElectronics Dr. Kotak was Chief Medical Officer of TraumaTec, a Houston medical device company, as well as a consultant to the Boss Group and Blackstone Valley Group, two private equity firms.
Dr. Kotak brings a broad medical background and health care perspective to the Company, having practiced as a specialist in intensive care medicine, anesthesia and trauma in a London teaching hospital. Dr. Kotak has also practiced for four years as a civil lawyer. Dr. Kotak holds degrees in medicine from Oxford University and the University of London.
CEOLIVE.TV is an online financial news portal focused on small cap publicly traded companies with a focus on undervalued stocks. Featuring short video interviews with CEOs, CFOs, Board Members and other corporate executives, CEOLIVE.TV gives investors the opportunity to learn about companies directly from the management team as well as access to detailed company profiles, video press releases and sector reports. To learn more, please visit www.ceolive.tv.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Forward Looking Statements
Certain information contained in this press release, including any information as to our strategy, plans or future financial or operating performance and other statements that express management's expectations or estimates of future performance, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Action of 1934. All statements, other than statements of historical fact, are forward-looking statements. The words "believe," "expect," "will," "anticipate," "contemplate," "target," "plan," "continue," "budget," "may," "intend," "estimate," "project" and similar expressions identify forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to its plans or operations. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the SEC which can be found at www.sec.gov. There may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
For Investor and Media Inquiries, please contact:
BioElectronics Corporation Investor Relations
E and E Communications
Email: [email protected]
SOURCE BioElectronics Corporation
Oct. 13, 2015 10:15 PM EDT Reads: 167
Oct. 13, 2015 09:00 PM EDT Reads: 263
Oct. 13, 2015 09:00 PM EDT Reads: 501
Oct. 13, 2015 08:45 PM EDT Reads: 274
Oct. 13, 2015 08:45 PM EDT Reads: 249
Oct. 13, 2015 08:30 PM EDT Reads: 149
Oct. 13, 2015 08:15 PM EDT Reads: 225
Oct. 13, 2015 08:00 PM EDT Reads: 279
Oct. 13, 2015 07:00 PM EDT Reads: 1,505
Oct. 13, 2015 07:00 PM EDT Reads: 286
Oct. 13, 2015 06:15 PM EDT Reads: 1,234
Oct. 13, 2015 06:00 PM EDT Reads: 555
Oct. 13, 2015 04:00 PM EDT Reads: 730
Oct. 13, 2015 03:15 PM EDT Reads: 260
Saviynt Inc. has announced the availability of the next release of Saviynt for AWS. The comprehensive security and compliance solution provides a Command-and-Control center to gain visibility into risks in AWS, enforce real-time protection of critical workloads as well as data and automate access life-cycle governance. The solution enables AWS customers to meet their compliance mandates such as ITAR, SOX, PCI, etc. by including an extensive risk and controls library to detect known threats and b...
Oct. 13, 2015 03:00 PM EDT Reads: 331